Healius Valuation

Is HLS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of HLS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: HLS (A$1.33) is trading below our estimate of fair value (A$7.29)

Significantly Below Fair Value: HLS is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for HLS?

Key metric: As HLS is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for HLS. This is calculated by dividing HLS's market cap by their current revenue.
What is HLS's PS Ratio?
PS Ratio0.6x
SalesAU$1.75b
Market CapAU$969.39m

Price to Sales Ratio vs Peers

How does HLS's PS Ratio compare to its peers?

The above table shows the PS ratio for HLS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1.3x
ACL Australian Clinical Labs
1x4.7%AU$683.3m
IDX Integral Diagnostics
1.5x6.6%AU$720.5m
CAJ Capitol Health
1.7x6.4%AU$405.1m
HLA Healthia
1xn/aAU$252.1m
HLS Healius
0.6x-4.2%AU$969.4m

Price-To-Sales vs Peers: HLS is good value based on its Price-To-Sales Ratio (0.6x) compared to the peer average (1.3x).


Price to Sales Ratio vs Industry

How does HLS's PS Ratio compare vs other companies in the AU Healthcare Industry?

3 CompaniesPrice / SalesEstimated GrowthMarket Cap
FCG Freedom Care Group Holdings
0.1xn/aUS$2.59m
HHI Health House International
0.05xn/aUS$590.30k
TTB Total Brain
0.03xn/aUS$179.68k
No more companies available in this PS range
HLS 0.6xIndustry Avg. 1.4xNo. of Companies3PS00.81.62.43.24+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: HLS is good value based on its Price-To-Sales Ratio (0.6x) compared to the Oceanic Healthcare industry average (1.4x).


Price to Sales Ratio vs Fair Ratio

What is HLS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

HLS PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.6x
Fair PS Ratio0.8x

Price-To-Sales vs Fair Ratio: HLS is good value based on its Price-To-Sales Ratio (0.6x) compared to the estimated Fair Price-To-Sales Ratio (0.8x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst HLS forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentAU$1.33
AU$1.55
+16.8%
21.3%AU$2.30AU$1.20n/a9
Nov ’25AU$1.58
AU$1.75
+10.6%
18.1%AU$2.50AU$1.37n/a9
Oct ’25AU$1.79
AU$1.77
-1.1%
18.8%AU$2.50AU$1.37n/a8
Sep ’25AU$1.67
AU$1.55
-7.0%
30.6%AU$3.00AU$1.00n/a12
Aug ’25AU$1.49
AU$1.37
-7.7%
36.2%AU$3.00AU$0.90n/a13
Jul ’25AU$1.43
AU$1.36
-5.2%
36.6%AU$3.00AU$0.90n/a13
Jun ’25AU$1.27
AU$1.37
+8.0%
35.8%AU$3.00AU$1.00n/a13
May ’25AU$1.16
AU$1.36
+18.1%
36.0%AU$3.00AU$1.00n/a13
Apr ’25AU$1.33
AU$1.37
+3.1%
35.9%AU$3.00AU$1.00n/a13
Mar ’25AU$1.17
AU$1.38
+18.3%
36.9%AU$3.00AU$1.00n/a12
Feb ’25AU$1.35
AU$1.56
+16.2%
29.4%AU$3.00AU$1.25n/a12
Jan ’25AU$1.65
AU$1.84
+12.0%
38.9%AU$3.45AU$1.20n/a11
Dec ’24AU$1.55
AU$1.84
+18.9%
38.9%AU$3.45AU$1.20n/a11
Nov ’24AU$1.85
AU$2.89
+56.8%
14.7%AU$3.55AU$2.30AU$1.5811
Oct ’24AU$2.31
AU$2.94
+27.2%
13.1%AU$3.55AU$2.40AU$1.7911
Sep ’24AU$2.77
AU$2.96
+7.1%
12.0%AU$3.55AU$2.48AU$1.6712
Aug ’24AU$2.88
AU$3.11
+8.0%
14.2%AU$4.00AU$2.60AU$1.4912
Jul ’24AU$3.16
AU$3.12
-1.0%
14.0%AU$4.00AU$2.60AU$1.4312
Jun ’24AU$3.10
AU$3.13
+0.9%
14.2%AU$4.05AU$2.60AU$1.2712
May ’24AU$3.06
AU$3.08
+0.6%
15.1%AU$4.10AU$2.60AU$1.1612
Apr ’24AU$3.16
AU$3.06
-3.2%
14.5%AU$4.00AU$2.60AU$1.3312
Mar ’24AU$2.70
AU$3.07
+13.6%
13.8%AU$4.00AU$2.60AU$1.1715
Feb ’24AU$3.16
AU$3.24
+2.6%
12.0%AU$4.15AU$2.75AU$1.3514
Jan ’24AU$3.07
AU$3.33
+8.7%
16.6%AU$4.80AU$2.65AU$1.6515
Dec ’23AU$2.94
AU$3.51
+19.4%
16.2%AU$4.80AU$2.70AU$1.5515
Nov ’23AU$3.47
AU$3.97
+14.5%
11.7%AU$4.80AU$3.18AU$1.8515

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies